StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
UPDATE: Citi Downgrades Merck (MRK) to Neutral
November 29, 2021 4:45 AM
(Updated - November 29, 2021 5:25 AM EST)
Citi analyst Andrew Baum downgraded Merck (NYSE: MRK) from Buy to ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Analyst Comments
Analyst PT Change
Downgrades
Next Articles
Merck (MRK) and Eisai Announces EU Approval of LENVIMA Plus KEYTRUDA as First-Line Treatment for Adult Patients With Advanced Renal Cell Carcinoma
November 29, 2021 5:52 AM
Merck (MRK) PT Lowered to $82 at Morgan Stanley
November 29, 2021 1:56 AM
It's Likely to Take Two Weeks to Understand 'Nu' Strain Impact, What We Know So Far - Morgan Stanley
November 26, 2021 9:11 AM
FDA posts briefing documents on Merck (MRK) /Ridgeback antiviral molnupiravir
November 26, 2021 9:07 AM
Merck (MRK), Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
November 26, 2021 6:46 AM
Merck and Ridgeback Biotherapeutics Provide Update on Results from MOVe-OUT Study of Molnupiravir, an Investigational Oral Antiviral Medicine, in At Risk Adults With Mild-to-Moderate COVID-19
November 26, 2021 6:45 AM
Pfizer (PFE), Other Coronavirus Vaccine/Antiviral Drug Stocks Climb on Virus Variant Fears
November 26, 2021 6:25 AM
